Twitter Facebook LinkedIn WhatsApp Press Releases (-) Any 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 Reset 2022 February 10, 2022 argenx to Present at the 11th Annual SVB Leerink Global Healthcare Conference January 20, 2022 argenx announces VYVGART™ approval in Japan for the treatment of generalized myasthenia gravis January 7, 2022 argenx Highlights Strategic Priorities for 2022 January 3, 2022 argenx to Present at 40th Annual J.P. Morgan Healthcare Conference 2021 December 17, 2021 argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis November 10, 2021 argenx to Present at Upcoming Investor Conferences October 28, 2021 argenx Reports Third Quarter 2021 Financial Results and Provides Business Update October 21, 2021 argenx to Report Third Quarter 2021 Financial Results and Business Update on October 28, 2021 October 8, 2021 argenx to Highlight Potential First-in-Class FcRn Antagonist Efgartigimod at Upcoming Neuromuscular Meetings September 2, 2021 argenx to Present at Upcoming Investor Conferences August 25, 2021 argenx Announces Validation of European Marketing Authorization Application for Efgartigimod in Generalized Myasthenia Gravis August 4, 2021 argenx to Present at 2021 Wedbush PacGrow Virtual Healthcare Conference Pagination First page « First Previous page ‹ Previous … Page 3 Page 4 Page 5 Page 6 Current page 7 Page 8 Page 9 Page 10 Page 11 … Next page Next › Last page Last »
